Bristol-Myers Squibb (BMY) Stock Forecast & Price Target

Compare

11,885 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BMY Analyst Ratings

Moderate Buy

7 Buy

12 Hold

1 Sell

Based on 20 analysts giving stock ratings to

Bristol-Myers

Squibb

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BMY Stock 12 Month Forecast

Average Price Target

$53.29

▲(1.68% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Bristol-Myers Squibb in the last 3 months. The average price target is $53.29 with a high forecast of $68.00 and a low forecast of $37.00. The average price target represents a 1.68% change from the last price of $52.41.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"36":"$36","69":"$69","44.25":"$44.3","52.5":"$52.5","60.75":"$60.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$68.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$53.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$37.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[36,44.25,52.5,60.75,69],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.18,50.62769230769231,52.075384615384614,53.52307692307692,54.97076923076923,56.418461538461536,57.86615384615385,59.31384615384616,60.761538461538464,62.20923076923077,63.65692307692308,65.10461538461539,66.55230769230769,{"y":68,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.18,49.496153846153845,49.81230769230769,50.128461538461536,50.44461538461538,50.76076923076923,51.07692307692307,51.393076923076926,51.70923076923077,52.02538461538462,52.34153846153846,52.65769230769231,52.973846153846154,{"y":53.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.18,48.24307692307692,47.30615384615385,46.36923076923077,45.432307692307695,44.495384615384616,43.558461538461536,42.621538461538464,41.684615384615384,40.747692307692304,39.81076923076923,38.87384615384615,37.93692307692308,{"y":37,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":57.1,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.88,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.78,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.42,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.36,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.77,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.79,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.18,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$68.00

Average Price Target$53.29

Lowest Price Target$37.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Seamus Fernandez

Guggenheim

$62

Buy

18.30%

Upside

Upgraded

12/12/25

Bristol Myers upgraded to Buy from Neutral at GuggenheimBristol Myers upgraded to Buy from Neutral at Guggenheim

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

12/12/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Immunovant (NASDAQ: IMVT) and Harmony Biosciences Holdings (NASDAQ: HRMY)

Terence Flynn

Morgan Stanley

$36→$37

Sell

-29.40%

Downside

Reiterated

12/12/25

Morgan Stanley Keeps Their Sell Rating on Bristol-Myers Squibb (BMY)

Matt Phipps

William Blair

―

Hold

―

Reiterated

12/11/25

Cautious Hold Rating on Bristol-Myers Squibb Amid Competitive Pressures in Hematology

Mohit Bansal

Wells Fargo

$53→$55

Hold

4.94%

Upside

Reiterated

12/10/25

Bristol-Myers Squibb (BMY) Receives a Hold from Wells Fargo

Rajesh Kumar

HSBC

$50→$53

Hold

1.13%

Upside

Reiterated

12/10/25

Bristol Myers price target raised to $53 from $50 at HSBCBristol Myers price target raised to $53 from $50 at HSBC

Louise Chen

Scotiabank

$53

Hold

1.13%

Upside

Reiterated

12/09/25

Bristol-Myers Squibb (BMY) Receives a Hold from Scotiabank

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$68

Buy

29.75%

Upside

Reiterated

12/04/25

Bristol-Myers Squibb (BMY) Gets a Buy from Jefferies

David Risinger

Leerink Partners

―

Buy

―

Reiterated

12/03/25

Leerink views ADEPT-2 update as positive news, keeps Outperform on Bristol MyersLeerink views ADEPT-2 update as positive news, keeps Outperform on Bristol Myers

Geoff Meacham

Citi

$45

Hold

-14.14%

Downside

Reiterated

12/03/25

Analysts Offer Insights on Healthcare Companies: Masimo (NASDAQ: MASI), Bristol-Myers Squibb (NYSE: BMY) and Johnson & Johnson (NYSE: JNJ)

Chris Schott

J.P. Morgan

―

Buy

―

Reiterated

12/03/25

Bristol Myers ADEPT-2 update an 'incremental positive,' says JPMorganBristol Myers ADEPT-2 update an 'incremental positive,' says JPMorgan

Evan Seigerman

BMO Capital

$47

Hold

-10.32%

Downside

Assigned

12/02/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY) and Phreesia (NYSE: PHR)Amid delays in ADEPT-2 and enrollment adjustments, we revise our target price to $47.00 while maintaining a Market Perform rating.

Asad Haider

Goldman Sachs

$51→$57

Hold

8.76%

Upside

Reiterated

12/02/25

Bristol Myers price target raised to $57 from $51 at Goldman SachsBristol Myers price target raised to $57 from $51 at Goldman Sachs

Courtney Breen

Bernstein

―

Hold

―

Reiterated

11/26/25

Analysts Offer Insights on Healthcare Companies: ClearPoint Neuro (NASDAQ: CLPT) and Bristol-Myers Squibb (NYSE: BMY)

Unknown Analyst

Berenberg Bank

Not Ranked

Berenberg Bank

$55

Hold

4.94%

Upside

Reiterated

11/25/25

Berenberg Bank Keeps Their Hold Rating on Bristol-Myers Squibb (BMY)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Seamus Fernandez

Guggenheim

$62

Buy

18.30%

Upside

Upgraded

12/12/25

Bristol Myers upgraded to Buy from Neutral at GuggenheimBristol Myers upgraded to Buy from Neutral at Guggenheim

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

12/12/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Immunovant (NASDAQ: IMVT) and Harmony Biosciences Holdings (NASDAQ: HRMY)

Terence Flynn

Morgan Stanley

$36→$37

Sell

-29.40%

Downside

Reiterated

12/12/25

Morgan Stanley Keeps Their Sell Rating on Bristol-Myers Squibb (BMY)

Matt Phipps

William Blair

―

Hold

―

Reiterated

12/11/25

Cautious Hold Rating on Bristol-Myers Squibb Amid Competitive Pressures in Hematology

Mohit Bansal

Wells Fargo

$53→$55

Hold

4.94%

Upside

Reiterated

12/10/25

Bristol-Myers Squibb (BMY) Receives a Hold from Wells Fargo

Rajesh Kumar

HSBC

$50→$53

Hold

1.13%

Upside

Reiterated

12/10/25

Bristol Myers price target raised to $53 from $50 at HSBCBristol Myers price target raised to $53 from $50 at HSBC

Louise Chen

Scotiabank

$53

Hold

1.13%

Upside

Reiterated

12/09/25

Bristol-Myers Squibb (BMY) Receives a Hold from Scotiabank

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$68

Buy

29.75%

Upside

Reiterated

12/04/25

Bristol-Myers Squibb (BMY) Gets a Buy from Jefferies

David Risinger

Leerink Partners

―

Buy

―

Reiterated

12/03/25

Leerink views ADEPT-2 update as positive news, keeps Outperform on Bristol MyersLeerink views ADEPT-2 update as positive news, keeps Outperform on Bristol Myers

Geoff Meacham

Citi

$45

Hold

-14.14%

Downside

Reiterated

12/03/25

Analysts Offer Insights on Healthcare Companies: Masimo (NASDAQ: MASI), Bristol-Myers Squibb (NYSE: BMY) and Johnson & Johnson (NYSE: JNJ)

Chris Schott

J.P. Morgan

―

Buy

―

Reiterated

12/03/25

Bristol Myers ADEPT-2 update an 'incremental positive,' says JPMorganBristol Myers ADEPT-2 update an 'incremental positive,' says JPMorgan

Evan Seigerman

BMO Capital

$47

Hold

-10.32%

Downside

Assigned

12/02/25

Asad Haider

Goldman Sachs

$51→$57

Hold

8.76%

Upside

Reiterated

12/02/25

Bristol Myers price target raised to $57 from $51 at Goldman SachsBristol Myers price target raised to $57 from $51 at Goldman Sachs

Courtney Breen

Bernstein

―

Hold

―

Reiterated

11/26/25

Analysts Offer Insights on Healthcare Companies: ClearPoint Neuro (NASDAQ: CLPT) and Bristol-Myers Squibb (NYSE: BMY)

Unknown Analyst

Berenberg Bank

Not Ranked

Berenberg Bank

$55

Hold

4.94%

Upside

Reiterated

11/25/25

Berenberg Bank Keeps Their Hold Rating on Bristol-Myers Squibb (BMY)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bristol-Myers Squibb

1 Month

xxx

Success Rate

11/20 ratings generated profit

Average Return

-1.57%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.00% of your transactions generating a profit, with an average return of -1.57% per trade.

3 Months

xxx

Success Rate

21/33 ratings generated profit

Average Return

+1.32%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +1.32% per trade.

1 Year

Terence FlynnMorgan Stanley

Success Rate

19/28 ratings generated profit

Average Return

+5.17%

reiterated a sell rating 3 days ago

Copying Terence Flynn's trades and holding each position for 1 Year would result in 67.86% of your transactions generating a profit, with an average return of +5.17% per trade.

2 Years

xxx

Success Rate

13/20 ratings generated profit

Average Return

+1.47%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 65.00% of your transactions generating a profit, with an average return of +1.47% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BMY Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BMY has received 20 Buy Ratings, 35 Hold Ratings, and 4 Sell Ratings. BMY average Analyst price target in the past 3 months is 53.29.

Each month's total comprises the sum of three months' worth of ratings.

BMY Financial Forecast

BMY Earnings Forecast

Next quarter’s earnings estimate for BMY is $1.62 with a range of $1.39 to $1.80. The previous quarter’s EPS was $1.63. BMY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year BMY has Performed in-line its overall industry.

BMY Sales Forecast

Next quarter’s sales forecast for BMY is $12.21B with a range of $11.87B to $12.53B. The previous quarter’s sales results were $12.22B. BMY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year BMY has Performed in-line its overall industry.

BMY Stock Forecast FAQ

What is BMY’s average 12-month price target, according to analysts?

Based on analyst ratings, Bristol-Myers Squibb’s 12-month average price target is 53.29.

What is BMY’s upside potential, based on the analysts’ average price target?

Bristol-Myers Squibb has 1.68% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BMY a Buy, Sell or Hold?

Bristol-Myers Squibb has a consensus rating of Moderate Buy which is based on 7 buy ratings, 12 hold ratings and 1 sell ratings.

What is Bristol-Myers Squibb’s price target?

The average price target for Bristol-Myers Squibb is 53.29. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $68.00 ,the lowest forecast is $37.00. The average price target represents 1.68% Increase from the current price of $52.41.

What do analysts say about Bristol-Myers Squibb?

Bristol-Myers Squibb’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of BMY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Bristol-Myers Squibb (BMY) Stock Forecast & Price Target

BMY Analyst Ratings

BMY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Bristol-Myers Squibb

BMY Analyst Recommendation Trends

BMY Financial Forecast

BMY Earnings Forecast

BMY Sales Forecast

BMY Stock Forecast FAQ

Detailed List of Analyst Forecasts